Skip to content

Study · Non-randomized trial · n = 38 · 2019

8 results

A new approach of ocular nebulization with vitamin B12 versus oxytocin for the treatment of dry eye disease: an in vivo confocal microscopy study.

Yang J, Liu Y, Xu Y, Li X, Fu J, Jiang X, Chou Y, Ma J, Hao R, Zhang R, Qiu W, Li X

Drug design, development and therapy18 Jul 2019Cited by 16 (Europe PMC)

PMID31409972 (opens in a new tab)PMCIDPMC6646855 (opens in a new tab)DOI10.2147/dddt.s203464 (opens in a new tab)PepBankPUB-31409972
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, tear break-up time was lower with oxytocin than with vitamin B12 nebulization at 1 month and 3 months.

    In plain wordsIn people with dry eye, tear break-up time was lower with oxytocin eye mist than with vitamin B12 eye mist.

    Peptide
    Oxytocin
    Outcome
    DecreaseTear break-up time versus vitamin B12
    Study

    n = 38

    Comparator
    Vitamin B12 nebulization
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    VB12 group revealed a higher BUT at 1 month and 3 months with a higher basal epithelial cell density at 3 months compared with OXT group, and a lower DC density was observed in OXT group at 1 month.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, basal epithelial cell density at 3 months was lower with oxytocin than with vitamin B12 nebulization.

    In plain wordsIn people with dry eye, oxytocin eye mist gave lower basal epithelial cell density at 3 months than vitamin B12 eye mist.

    Peptide
    Oxytocin
    Outcome
    DecreaseBasal epithelial cell density at 3 months versus vitamin B12
    Study

    n = 38

    Comparator
    Vitamin B12 nebulization
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    with a higher basal epithelial cell density at 3 months compared with OXT group, and a lower DC density was observed in OXT group at 1 month.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, dendritic cell density at 1 month was lower with oxytocin than with vitamin B12 nebulization.

    In plain wordsIn people with dry eye, oxytocin eye mist gave lower immune dendritic cell density at 1 month than vitamin B12 eye mist.

    Peptide
    Oxytocin
    Outcome
    DecreaseDendritic cell density at 1 month versus vitamin B12
    Study

    n = 38

    Comparator
    Vitamin B12 nebulization
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    a lower DC density was observed in OXT group at 1 month.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, the change of basal epithelial cell density at 3 months was smaller with oxytocin than with vitamin B12 nebulization.

    In plain wordsIn people with dry eye, basal epithelial cell density changed less with oxytocin eye mist than with vitamin B12 eye mist.

    Peptide
    Oxytocin
    Outcome
    DecreaseChange of basal epithelial cell density at 3 months versus vitamin B12
    Study

    n = 38

    Comparator
    Vitamin B12 nebulization
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Change of basal epithelial cell density was more significant at 3 months in VB12 group, with OXT group showing a significantly higher DC reduction at 1 month.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, oxytocin nebulization produced a significantly greater reduction of dendritic cell density at 1 month than vitamin B12.

    In plain wordsIn people with dry eye, oxytocin eye mist cut dendritic cell density more at 1 month than vitamin B12 eye mist.

    Peptide
    Oxytocin
    Outcome
    DecreaseChange of dendritic cell density at 1 month versus vitamin B12
    Study

    n = 38

    Comparator
    Vitamin B12 nebulization
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    with OXT group showing a significantly higher DC reduction at 1 month.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, twice-weekly oxytocin nebulization for 3 months improved clinical signs, symptoms and confocal microscopy measures, except break-up time and nerve tortuosity.

    In plain wordsIn people with dry eye, oxytocin eye mist improved most signs and symptoms over 3 months, but not tear break-up time or nerve tortuosity.

    Peptide
    Oxytocin
    Outcome
    MixedDry eye signs and symptoms except break-up time and nerve tortuosity
    Study

    n = 19

    Comparator
    Baseline
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    OXT demonstrated similar effects apart from BUT and nerve tortuosity.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, oxytocin nebulization did not significantly improve tear break-up time.

    In plain wordsIn people with dry eye, oxytocin eye mist did not significantly improve tear break-up time.

    Peptide
    Oxytocin
    Outcome
    No significant changeTear break-up time (BUT)
    Study

    n = 19

    Comparator
    Baseline
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    OXT demonstrated similar effects apart from BUT and nerve tortuosity.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with dry eye disease, oxytocin nebulization did not significantly improve nerve tortuosity.

    In plain wordsIn people with dry eye, oxytocin eye mist did not significantly improve nerve tortuosity.

    Peptide
    Oxytocin
    Outcome
    No significant changeNerve tortuosity
    Study

    n = 19

    Comparator
    Baseline
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated · ocular nebulization · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    OXT demonstrated similar effects apart from BUT and nerve tortuosity.
    1 context sentence
    Summary · context
    Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.